Description
Overview
Tirzepatide is a peptide engineered to activate both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual-incretin design has been extensively studied in type 2 diabetes, chronic weight management, obstructive sleep apnea associated with obesity, and broader cardiometabolic research. It influences glucose-dependent insulin signaling, glucagon regulation, appetite pathways, and gastrointestinal motility. FDA approvals belong to specific prescription products and indications, not to separately supplied research material.
How It Works
- GIP receptor signaling: Adds glucose-dependent insulinotropic and metabolic signaling through the GIP pathway.
- GLP-1 receptor signaling: Affects insulin/glucagon balance, appetite, satiety, and gastrointestinal signaling.
Research Areas
- Type 2 diabetes
- Chronic weight management
- Obesity-related sleep apnea
- Cardiometabolic outcomes
Research / Study Context
- SURPASS program: Large randomized diabetes trials evaluated glycemic control, body weight, and safety.
- SURMOUNT program: Obesity trials evaluated body weight, cardiometabolic risk markers, and obesity-related conditions.
Key Research Findings
- Tirzepatide has a large human clinical evidence base.
- Adverse effects and contraindications are product- and indication-specific.
- Apex RUO material is not Mounjaro, Zepbound, or a substitute for them.
- Semaglutide
- Retatrutide
- Cagrilintide
Scientific Reference Starter Set
- Peptide Education Hub: Tirzepatide profile
- PubMed: SURMOUNT-1 tirzepatide obesity
- FDA prescribing information: Mounjaro / Zepbound
